You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Nitric Oxide Microfluidic Sensor
SBC: CLINICAL SENSORS, INC. Topic: NIAIDDESCRIPTION provided by applicant This Small Business Innovation Research SBIR Phase I project aims to develop a microfluidic based nitric oxide NO sensor as an early sepsis risk assessment device Sepsis causes significant strain on the U S healthcare system consuming over $ billion annually due to extended hospital stays and significant morbidity and mortality Rapid diagnosis and in ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
RNA Detection as an Improved Diagnostic Assay for Human Leptospirosis
SBC: L2 DIAGNOSTICS LLC Topic: NIAIDDESCRIPTION provided by applicant Leptospirosis a zoonotic disease is an important public health problem worldwide It is caused by spirochete bacteria belonging to nine species and more than serovars of the genus Leptospira In the US there is increasing awareness of the importance of leptospirosis as the cause of disease among inner city populations military personnel and individuals ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
A Multivalent Lyme Disease Vaccine Targeting Tick-Host-Pathogen Interactions
SBC: L2 DIAGNOSTICS LLC Topic: NIAIDDESCRIPTION provided by applicant This proposal seeks to develop a novel vaccine against Lyme disease by targeting Ixodes scapularis proteins critical for Borrelia burgdorferi transmission from the tick to mammalian host Earlier work has identified four tick proteins Salp TRE tHRF and TSLPI that facilitate different steps of spirochete transmission and immunity against these protein ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of Peptide Antibiotic Nucleic Acids
SBC: NUBAD LLC Topic: NIAIDDESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Bioscience Research Integration Software Platform
SBC: BIOFORTIS, INC. Topic: N/ADESCRIPTION (provided by applicant): The need to investigate and understand all elements of biological information pertinent to disease is more clearly evident now than ever before. However, the avalanche of non-integrated data produced by today's technologies prevents scientists from effectively reducing these data to meaningful discoveries. As a result, the vast bulk of data collected through ...
STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
Novel Treatment for Septicemia Targets A1 ARs
SBC: ENDACEA, INC Topic: N/ADESCRIPTION (provided by applicant): Septicemia is a medical syndrome characterized by an overwhelming systemic response to infection that can rapidly lead to shock, organ failure and death. In the U.S. septicemia is the 10th leading cause of death overall with over 750,000 cases and 215,000 deaths each year and accounts for $17 billion in annual health care expenditures. Following its release fr ...
STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
Antisense Treatment for Thalassemia. Preclinical study.
SBC: ERCOLE BIOTECH, INC. Topic: N/ADESCRIPTION (provided by applicant): The ultimate goal of this project is treatment of beta-thalassemia, a genetic blood disease, with antisense oligonucleotides. The project is based on the technology developed by the PI in which antisense oligonucleotides are used to restore correct functioning of a defective gene rather than, as commonly practiced, to inhibit the expression of an undesirable ge ...
STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
AAV2-ASPA-Based Metabolic Intervention for Alzheimer's Disease
SBC: ASKLEPIOS BIOPHARMACEUTICAL, INC. Topic: NIAAbstract We propose to initiate preclinical development of a gene therapeutic targeted to Alzheimer's Disease. The World Health Organization's and Alzheimer's Disease International's report on Dementia (2012) recognizes that the global burden of AlzheimerDisease is forecast to worsen significantly with prevalence predicted to double every 20 years. Interventions that could prov ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Picture Me Fit: Engaging Youth in Community-Based Prevention
SBC: PREVENTION STRATEGIES, LLC Topic: 600DESCRIPTION provided by applicant Approximately one third of all U S adults and children are obese and at risk for a wide range of related chronic health conditions such as cardiovascular disease hypertension diabetes stroke osteoarthritis sleep apnea and certain types of cancer The Center for Disease Control and Prevention CDC and other expert resources recognize that although indivi ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of VPL Vaccine for RSV
SBC: SIGMOVIR BIOSYSTEMS, INC. Topic: NIAIDProject Summary Human respiratory syncytial virus (RSV) is recognized as the single most important viral cause of acute respiratory disease in infants and young children worldwide. Elderly populations and immunocompromised individuals are also at significant risk for serious RSV disease. Despite this very substantial disease burden imposed by RSV worldwide, there are no vaccines available. Severa ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health